Since the first EGFR targeting antibody panitumumab (Vectibix) from humanized mice has obtained regulatory approval in 2005, dozens of additional transgenic mouse-derived mAbs have entered human clinical testing, i.e., CD20 (Ofatumumab), CD4 (Zanolimumab), CD70, etc. These genetically "humanized" animals have become one of the most powerful strategies for therapeutic/ diagnostic antibody development, which is now the fastest growing group of mAb drugs in clinical trials currently.

1. transgenic mice service
• As one forward-looking research institute as well as a leading custom service provider, Creative Biolabs has
established the innovative Magic™ Human Antibody Discovery Platform using transgenic mice/rats. We have
integrated multiple first-class “humanized” animals, in combination with our elegant antibody generation
technologies, to contribute the discovery and development of fully human antibodies for global clients.
• By introducing human immunoglobulin loci (heavy and light chains) into the mouse germlines with
inactivated/disrupted endogenous antibody machinery, the transgenic mouse/rat strains can directly generate high
affinity, fully human antibodies, which avoid the subsequent costly and tedious in vitro humanization and affinity
maturation process. Upon immunization, the Ig transgenes will undergo V(D)J rearrangement, random nucleotide
(N region) addition, class switching, and somatic hypermutation to yield impeccable antibodies. This technology
takes advantage of the naturally intact immune system with robust response, high-efficient selection and in vivo
maturation while maintaining fully humanness which can eliminate immunogenicity concerns.

2. • Since the first EGFR targeting antibody panitumumab (Vectibix) from
humanized mice has obtained regulatory approval in 2005, dozens of
additional transgenic mouse-derived mAbs have entered human
clinical testing, i.e., CD20 (Ofatumumab), CD4 (Zanolimumab), CD70,
etc. These genetically "humanized" animals have become one of the
most powerful strategies for therapeutic/ diagnostic antibody
development, which is now the fastest growing group of mAb drugs in
clinical trials currently.

3. • Compared with conventional approaches, using transgenic animals can offer following advantages:
• More robust antibody production (in vivo immune machinery compared to artificial engineering process)
• Optimized properties due to in vivo selection and affinity maturation
• No need for tedious and risky humanization and affinity improvement
• Low immune tolerance to human antigens (rodent background)
• Easy to operate
• Creative Biolabs is now accessible to multiple well-established transgenic mouse/rats strains with different genetic
backgrounds to allow selecting over different antibody repertoires. In addition, these “humanized” animals have
been optimized to enable strong and potent immune responses. Both conventional Igs and human sdAbs can be
generated from these transgenic mice. A series of impressive success records against a variety of targets (e.g.
cytokines, viral proteins, membrane receptors, etc.) can be tracked.

4. • Equipped with these unparalleled resources, Magic™ human antibody
platform provides one-round services utilizing several state-of-the-art
technologies for discovery of impeccable antibody candidates, including
transgenic mouse/rat hybridoma technology, transgenic phage display library
technology, as well as Native™ antibody discovery platform (plasma cell
sorting), to facilitate diverse research objectives.
• With vast experience and enthusiasm in human antibody development and
engineering, Creative Biolabs has always been devoted to delivering best-in-
class services to our worldwide customers. Our scientists are happy to discuss
with you to tailor a most appropriate plan for your project. Please feel free to
inquiry us for more details.